<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02167594</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-1451-A09</org_study_id>
    <nct_id>NCT02167594</nct_id>
  </id_info>
  <brief_title>Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers</brief_title>
  <official_title>18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate 18F-AV-1451 for brain imaging of tau in subjects with progressive
      supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>18F-AV-1451 imaging in PSP, CBD and Healthy Volunteers</measure>
    <time_frame>75-105 minutes post injection</time_frame>
    <description>Compare standard uptake value ratio (SUVR) by diagnostic group (PSP, CBD and healthy volunteers).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <condition>Corticobasal Degeneration</condition>
  <arm_group>
    <arm_group_label>PSP Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose of florbetapir F 18 at screening. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of 18F-AV-1451 at baseline and at 9 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at screening. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of 18F-AV-1451 at baseline and at 9 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of 18F-AV-1451 at baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-AV-1451</intervention_name>
    <arm_group_label>PSP Subjects</arm_group_label>
    <arm_group_label>CBD subjects</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <other_name>T807</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>florbetapir F18</intervention_name>
    <arm_group_label>PSP Subjects</arm_group_label>
    <arm_group_label>CBD subjects</arm_group_label>
    <other_name>Amyvid</other_name>
    <other_name>18F-AV-45</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cognitively Healthy Volunteers

          -  Mini-mental state examination (MMSE) ≥ 28

          -  No history of cognitive decline or parkinsonian motor disorder

        CBD and PSP subjects

          -  Able to walk 10 steps with minimal assistance

          -  MMSE ≥ 14 and ≤ 30

          -  Subject has a reliable study partner who agrees to accompany subject to visits and
             spends at least 5 hours per week with the subject

        PSP subjects only

          -  Meet National Institute of Neurological Disorders and Stroke - Society for Progressive
             Supranuclear Palsy (NINDS-SPSP) probable or possible PSP criteria as modified for the
             Neuroprotection and Natural History Parkinson Plus Syndromes (NNIPPS) clinical trial

        CBD subjects only

          -  Meets 2013 consensus criteria for possible or probably corticobasal degeneration,
             corticobasal syndrome (CBS) subtype

        Exclusion Criteria:

        All subjects

          -  Have evidence of structural abnormalities such as vascular disease, large strokes or
             severe white matter disease or other mass lesion on screening MRI

          -  Claustrophobia

          -  Current clinically significant cardiovascular disease or clinically significant
             abnormalities on screening ECG (e.g. QTC&gt;450 msec)

          -  Have a history of risk factors for Torsades de Pointes (e.g. heart failure,
             hypokalemia, family history of long QT syndrome)

          -  Have a current clinically significant infectious disease, endocrine or metabolic
             disease, pulmonary, renal or hepatic impairment, or cancer

          -  Females of childbearing potential who are not surgically sterile, not refraining from
             sexual activity or not using reliable methods of contraception

          -  Have received or participated in a trial with investigational medications in the past
             30 days

          -  Have had a non-study related radiopharmaceutical imaging or treatment procedure within
             7 days prior to the study imaging session

          -  Have a history of neuroleptic use for a prolonged period of time or within the past 6
             months

        PSP and CBD subjects

          -  Have evidence of amyloid deposition

          -  Meet National Institute on Aging-Alzheimer's Association criteria for probable
             Alzheimer's Disease

          -  Have any other neurological condition other than CBS or PSP that could account for
             cognitive or motor deficits

          -  Serum or plasma progranulin level less than one standard deviation below the normal
             subject mean for the laboratory performing the assay

          -  Have a high-rsk family history suggestive of TDP-43 pathology or known mutations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Movement Disorder Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Neurosciences Clinical Research Unit</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Molecular Neuroimaging</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perelman School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2014</study_first_submitted>
  <study_first_submitted_qc>June 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2014</study_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

